Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acorda Therapeutics, Inc.
Acorda Therapeutics Names Anthony Caggiano Vice President, Preclinical Development
May 1st, 2009
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced Anthony Caggiano, M.D., PhD., has been promoted to Vice President, Preclinical Development and joined the Company’s management team. Dr. Caggiano will continue to manage the Preclinical and Research & Development departments, as well as oversee Acorda’s preclinical programs that aim to develop novel approaches to the treatment of multiple sclerosis (MS), spinal cord injury (SCI) and related neurological disorders. “Since joining Acorda, Tony has made significant contributions in advancing our preclinical technologies, bringing novel and exciting protein therapeutics closer to clinical stage trials,” said Ron Cohen,...
Source: Health Business Week (2009-05-01)
|
